Bayer AG (OTC:BAYRY) Q1 Earnings Analysis: Agricultural Growth Powers Strong Quarter Despite P/E Challenges

• Bayer AG (OTC:BAYRY) reported strong Q1 2026 earnings, with earnings per share of $0.80 and revenue of $15.79 billion, both exceeding analyst estimates.
• The positive performance was primarily driven by its agricultural science division, which boosted operating profit by 9%.

Bayer AG (OTC:BAYRY) is a prominent German life science company with a global presence. Its core business activities are strategically divided into three key areas: pharmaceuticals, consumer health products, and agricultural science, also known as Crop Science. The company actively develops and sells a wide range of innovative products across these vital sectors.

On May 12, 2026, Bayer AG reported strong quarterly results. The company announced an earnings per share of $0.80, which significantly surpassed the analyst estimate of $0.64. Additionally, its revenue came in at $15.79 billion, slightly exceeding the consensus estimate of $15.77 billion for the quarter, demonstrating robust financial performance.

This positive financial performance was largely attributed to its thriving agricultural business. As highlighted by Reuters, Bayer AG's first-quarter operating profit saw a substantial 9% increase, primarily driven by this division's strong contribution. The Wall Street Journal also reported that the surge in net profit was further fueled by significant growth in its agricultural unit and a strategic gain from selling an antibiotics business.

Examining its overall financial health, Bayer AG exhibits a debt-to-equity ratio of 1.44. This significant ratio indicates that the company relies more on debt than equity to finance its operational assets, impacting its balance sheet structure. Furthermore, its current ratio is 0.996, which suggests that its short-term assets are nearly equal to its short-term liabilities, providing insights into its immediate liquidity position.